CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
The Endogenex Devicedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05014204
NCT05014204N/ACompleted

Safety and Feasibility of Endoscopic Application of a Novel Therapy for Duodenal Mucosal Regeneration in the Treatment of Type II Diabetes

Endogenex, Inc.·interventional·Posted Aug 20, 2021·Updated Dec 22, 2025

In Brief

A clinical study evaluating The Endogenex Device for Diabetes and 6 related conditions. Completed, enrolled 20 participants across 3 sites.

Detailed Summary

This is a multi-center, open-label study to assess the feasibility and preliminary safety of the Endogenex Device for endoscopic duodenal mucosal regeneration in patients with type 2 Diabetes inadequately controlled on 2-3 non-insulin glucose-lowering medications.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedAug 20, 2021
Enrollment StartOct 29, 2021
Primary CompletionMay 29, 2024
Study CompletionMay 29, 2025
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 4.9 years ago

Interventions

The Endogenex Devicedevice

The Endogenex device is designed to induce duodenal mucosal regeneration using pulsed electric field. The Endogenex procedure is a non-surgical, endoscopic procedure.